Coenzyme M

Generic Name: Coenzyme M

Brand Names: Uromitexan

Drug Type: Small Molecule

Chemical Formula: C_₂H_₆O_₃S_₂

CAS Number: 3375-50-6

Unique Ingredient Identifier: VHD28S0H7F

Background: Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

Indication: Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

Associated Conditions: Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide

Associated Therapies: -

Clinical Trials

Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

Phase 1

Terminated

Conditions: MYOPATHY

Interventions: Biological: Hematopoietic stem cell transplantation
Drug: Cyclophosphamide
Drug: Mesna
Drug: ATG(rabbit)
Drug: Methylprednisolone
Drug: G-CSF
Drug: Rituxan

First Posted Date: 2006-01-18

Last Posted Date: 2018-08-06

Lead Sponsor: Northwestern University

Target Recruit Count: 7

Registration Number: NCT00278564

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Hematopoietic Stem Cell Support in Vasculitis

Phase 1

Terminated

Conditions: Vasculitis

Interventions: Biological: Autologous Stem Cell Transplant
Biological: Allogeneic Stem Cell Transplant
Drug: Cyclophosphamide
Drug: ATG (rabbit)
Drug: Campath-1h
Drug: G-CSF
Drug: Fludarabine
Drug: Mesna
Drug: Tacrolimus

First Posted Date: 2006-01-18

Last Posted Date: 2018-08-02

Lead Sponsor: Northwestern University

Target Recruit Count: 7

Registration Number: NCT00278512

Locations: 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States

Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas

Phase 2

Completed

Conditions: Neuroblastoma
Ewings Sarcoma
Non-rhabdomyosarcoma Soft Tissue Sarcoma

First Posted Date: 2005-09-14

Last Posted Date: 2009-11-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00165139

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Phase 2

Terminated

Conditions: Burkitt Lymphoma
Non-Hodgkins Lymphoma
Atypical Burkitt Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Methotrexate
Drug: Leucovorin
Drug: Cytarabine
Drug: Ifosfamide
Drug: Etoposide
Drug: Mesna

First Posted Date: 2005-08-03

Last Posted Date: 2013-05-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT00126191

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Phase 1

Terminated

Conditions: Kidney Neoplasms

First Posted Date: 2004-09-13

Last Posted Date: 2012-10-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00091611

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma

Phase 2

Completed

Conditions: Sarcoma

First Posted Date: 2004-09-02

Last Posted Date: 2014-01-24

Lead Sponsor: Radiation Therapy Oncology Group

Registration Number: NCT00002791

Locations: 🇺🇸
Veterans Affairs Medical Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸
Harbor Hospital Center, Baltimore, Maryland, United States

and more 234 locations

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-31

Last Posted Date: 2010-10-01

Lead Sponsor: Temple University

Registration Number: NCT00002509

Locations: 🇺🇸
Temple University Cancer Center, Philadelphia, Pennsylvania, United States

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1

Conditions: Breast Cancer

First Posted Date: 2004-08-31

Last Posted Date: 2014-01-10

Lead Sponsor: St. Louis University

Target Recruit Count: 50

Registration Number: NCT00002628

Locations: 🇺🇸
Methodist Hospital-Central Unit, Memphis, Tennessee, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸
St. Louis University Health Sciences Center, Saint Louis, Missouri, United States

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

First Posted Date: 2004-08-23

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT00002634

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

First Posted Date: 2004-08-23

Last Posted Date: 2010-10-01

Lead Sponsor: Temple University

Registration Number: NCT00002510

Locations: 🇺🇸
Temple University Cancer Center, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy